Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The protein kinase B-RAF is a human oncogene that is mutated in ∼70% of human melanomas and transforms mouse melanocytes. Microphthalmia-associated transcription factor (MITF) is an important melanocyte differentiation and survival factor, but its role in melanoma is unclear. In this study, we show that MITF expression is suppressed by oncogenic B-RAF in immortalized mouse and primary human melanocytes. However, low levels of MITF persist in human melanoma cells harboring oncogenic B-RAF, suggesting that additional mechanisms regulate its expression. MITF reexpression in B-RAF–transformed melanocytes inhibits their proliferation. Furthermore, differentiation-inducing factors that elevate MITF expression in melanoma cells inhibit their proliferation, but when MITF up-regulation is prevented by RNA interference, proliferation is not inhibited. These data suggest that MITF is an antiproliferation factor that is down-regulated by B-RAF signaling and that this is a crucial event for the progression of melanomas that harbor oncogenic B-RAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MITF protein expression is suppressed by BRAFV600E in melanocytes and melanomas, however, which allows cell proliferation48,56.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 6×
“5 D, lanes 1, 2, 5, and 6) and in two melanoma cell lines that express oncogenic B-RAF (Davies et al., 2002), and this is accompanied by reduced proliferation (Fig.”
BackgroundInfluentialSelf-citationThe RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228 · cited 8×
“Cells were transfected as described previously (Wellbrock et al., 2004b) using 20–120 nM A-RAF, C-RAF, scrambled (Karasarides et al., 2004), B-RAF (5 -AACAGUCUACAAGGGAAAGUG-3 ), or melanocyte-specific”
BackgroundMethodInfluentialSelf-citationMcGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760 · cited 2×
“We propose that MITF function cannot be completely abolished in melanoma and that low level expression must be maintained to stimulate survival and/or proliferation, possibly by regulating BCL2 (McGill et al., 2002) and CDK2 (Du et al., 2004) expression.”
BackgroundMAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 630 · cited 3×
“2 B); these effects were previously attributed to ERK-dependent phosphorylation on S73 (Hemesath et al., 1998).”
BackgroundMethodInfluentialWu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 527 · cited 7×
“Previous studies have shown that ERK phosphorylates S73 of MITF, targeting it for degradation (Wu et al., 2000; Xu et al., 2000), so we analyzed whether this mechanism underlies MITF loss in our cell lines.”
BackgroundResultInfluentialMicrophthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes
Bertolotto, C., Abbe, P., Hemesath, T. J., Bille, K., Fisher, D. E., Ortonne, J.-P., & Ballotti, R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.142.3.827 · Cited by 512 · cited 4×
“For example, the differentiation factor -melanocyte–stimulating hormone strongly increases its expression in a cAMP and cAMP response element binding protein (CREB) transcription factor–dependent manner (Bertolotto et al., 1998).”
BackgroundInfluentialSuppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426 · cited 6×
“Cells were transfected as described previously (Wellbrock et al., 2004b) using 20–120 nM A-RAF, C-RAF, scrambled (Karasarides et al., 2004), B-RAF (5 -AACAGUCUACAAGGGAAAGUG-3 ), or melanocyte-specific”
BackgroundMethodInfluentialSelf-citationDu, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421 · cited 2×
“Importantly, forskolin-induced MITF expression (Fig.”
BackgroundDown-regulation of the novel gene melastatin correlates with potential for melanoma metastasis.
Duncan, L. M., Deeds, J. D., Hunter, J., Shao, J., Holmgren, L. M., Woolf, E. A., Tepper, R. I., & Shyjan, A. W. (1998) · PubMed · Cited by 401
Cited by
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
“These include those encoding the transcription factors MITF (microphthalmia-associated transcription factor”
BackgroundSelf-citationOncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
“The relationship between BRAF and MITF is poorly understood because oncogenic BRAF and the ERK pathway promote MITF activation but also lead to its degradation (Hemesath et al., 1998; Wu et al., 2000; Wellbrock and Marais, 2005; Wellbrock et al., 2008; Boni et al., 2010).”
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
“The anti-proliferative role of Mitf is also underscored by the observation that activated BRAF expression can suppress Mitf expression and that increasing Mitf expression in melanomas leads to decreased proliferation (Wellbrock and Marais 2005).”
BackgroundHoek, K. S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 555
“This likely lies in B-raf’s role as a mediator of c-Kit activated Raserk signalling (Linnekin, 1999) which is a regulator of melanocytic cell proliferation (Wellbrock and Marais, 2005).”
BackgroundA Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma
Caramel, J., Papadogeorgakis, E., Hill, L., Browne, G. J., Richard, G., Wierinckx, A., Saldanha, G., Osborne, J., Hutchinson, P., Tse, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.018 · Cited by 517
Cancer stem cells versus phenotype‐switching in melanoma
Hoek, K. S., & Goding, C. R. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00757.x · Cited by 506
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
“Indeed, mutant BRAF has been shown to down-regulate MITF levels (Wellbrock and Marais 2005), and correspondingly, MITF overexpression (in a specific context) could inhibit growth-stimulatory effects of mutant BRAF.”
BackgroundGoding, C. R., & Arnheiter, H. (2019) · Genes & Development · doi:10.1101/gad.324657.119 · Cited by 430
“Furthermore, both Hemesath et al. (1998) and Wellbrock and Marais (2005) have shown that an S73A mutation does not affect MITF protein stability, at least in the assays undertaken.”
Resistance to BRAF-targeted therapy in melanoma
Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 374
Felicetti, F., Errico, M. C., Bottero, L., Segnalini, P., Stoppacciaro, A., Biffoni, M., Felli, N., Mattia, G., Petrini, M., Colombo, M. P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2538 · Cited by 377
“Finally, we point out that MITF is, on average, expressed at significantly lower level in melanomas than in melanocytes and that increased levels of MITF seem to reduce melanoma proliferation even in the presence of mutated B-RAF (38).”
BackgroundPhenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Self-citationMechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
Delmas, V., Beermann, F., Martinozzi, S., Carreira, S., Ackermann, J., Kumasaka, M., Denat, L., Goodall, J., Luciani, F., Viros, A., et al. (2007) · Genes & Development · doi:10.1101/gad.450107 · Cited by 311
“2006) while high levels inhibit cell division (Carreira et al. 2005; Loercher et al. 2005; Wellbrock and Marais 2005).”
BackgroundThe master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology
Kawakami, A., & Fisher, D. E. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.9 · Cited by 326
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 304
“However, RAS mutations do occur early in melanoma development (43) and we have previously reported the unusual finding that both BRAF and CRAF contribute to MEK signaling in SkMel2 cells (44), a melanoma cell line that harbors a mutation in K-RAS (Table 1).”
BackgroundSelf-citationOncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., & Marais, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002734 · Cited by 278
“. We have previously shown that the differentiation functions of MITF occur at high protein concentrations, and accordingly, high levels of MITF are anti-proliferative in melanoma cells”
BackgroundSelf-citationBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“Melanocyte cell lines with activated MEK/ERK signalling, for example as a result of BRAFE600 overexpression, downregulate MITF and produce less pigment (Wellbrock and Marais, 2005).”
BackgroundSmith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
“Importantly, not only are MITF focal amplifications significantly linked to the BRAF mutant melanoma subtype (Cancer Genome Atlas Network, 2015), but the expression of MITF is also tightly regulated by BRAF-initiated MAPK signaling (Wellbrock and Marais, 2005; Wellbrock et al., 2008).”
BackgroundSelf-citationWellbrock, C., & Arozarena, I. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12370 · Cited by 217
“Moreover, ectopic expression of BRAFV600E in human melanocytes reduces MITF protein levels (Wellbrock and Marais, 2005).”
InfluentialSelf-citationMITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells
Ploper, D., Taelman, V. F., Robert, L., Perez, B. S., Titz, B., Chen, H.-W., Graeber, T. G., von Euw, E., Ribas, A., & De Robertis, E. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424576112 · Cited by 228
“As a melanocyte master regulator, MITF drives cells toward differentiation, and high MITF levels have antiproliferative effects (61).”
BackgroundGoodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R. A., Larue, L., & Goding, C. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1053 · Cited by 208
Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C., & Sahai, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0781 · Cited by 202
Self-citationPalmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 177
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells
Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V, Hofman, P., Bahadoran, P., Lacour, J.-P., Tartare-Deckert, S., Bertolotto, C., et al. (2012) · Oncogene · doi:10.1038/onc.2011.425 · Cited by 185
“One can also suggest that very high MITF expression, which might be induced by Forskolin, causes the inhibition of tumour growth (Wellbrock and Marais, 2005; Carreira et al., 2006).”
BackgroundBRAF as therapeutic target in melanoma
Wellbrock, C., & Hurlstone, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.019 · Cited by 178
Self-citationThe genome and epigenome of malignant melanoma
DAHL, C., & GULDBERG, P. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 162
Martina, J. A., Diab, H. I., Li, H., & Puertollano, R. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1565-8 · Cited by 158
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma
Hsiao, J. J., & Fisher, D. E. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.019 · Cited by 148
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Ibrahim, N., & Haluska, F. G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151541 · Cited by 138
Melanoma: Molecular pathogenesis and emerging target therapies (Review)
Libra (2009) · International Journal of Oncology · doi:10.3892/ijo_00000277 · Cited by 136
“It has been shown that constitutive ERK activity, stimulated by V600EBRAF in melanoma cells, is associated with MITF ubiquitin-dependent degradation (59).”
Kono, M., Dunn, I. S., Durda, P. J., Butera, D., Rose, L. B., Haggerty, T. J., Benson, E. M., & Kurnick, J. T. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0077 · Cited by 141
“resolution to this seeming paradox, Wellbrock and Marais (41) proposed that low but definite amounts of MITF-M are required for melanoma survival and/or proliferation.”
BackgroundInfluentialFunctional Proteomics Identifies Targets of Phosphorylation by B-Raf Signaling in Melanoma
Old, W. M., Shabb, J. B., Houel, S., Wang, H., Couts, K. L., Yen, C.-Y., Litman, E. S., Croy, C. H., Meyer-Arendt, K., Miranda, J. G., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.03.007 · Cited by 136
“These include cyclin D1, Brn2, and microphthalmia-associated transcription factor (MITF), which modulate cell proliferation (Bhatt et al., 2005; Goodall et al., 2004; Wellbrock and Marais, 2005); and HIF1a, Bim1, and PUMA, which regulate cell survival against apoptotic cell stress (Wang et al.”
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
Wellbrock, C., & Arozarena, I. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00033 · Cited by 145
“However, ERK phosphorylation can also trigger ubiquitin-mediated degradation (Wu et al., 2000), and as a result of sustained ERK activation MITF protein levels are reduced, a situation that is compatible with proliferation (Wellbrock and Marais, 2005).”
BackgroundSelf-citationIn melanoma, beta-catenin is a suppressor of invasion
Arozarena, I., Bischof, H., Gilby, D., Belloni, B., Dummer, R., & Wellbrock, C. (2011) · Oncogene · doi:10.1038/onc.2011.162 · Cited by 121
Self-citationPasseron, T., Valencia, J. C., Namiki, T., Vieira, W. D., Passeron, H., Miyamura, Y., & Hearing, V. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci34015 · Cited by 116
“This effect is achieved by 2 distinct mechanisms: (a) an indirect effect, whereby SOX9 activates MITF, which in turn acts on p21 and blocks melanoma proliferation (9, 11); and (b) a direct effect, whereby SOX9 directly binds the p21 promoter and increases its expression.”
BackgroundmiR-148 Regulates Mitf in Melanoma Cells
Haflidadóttir, B. S., Bergsteinsdóttir, K., Praetorius, C., & Steingrímsson, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011574 · Cited by 130
“Consistent with this, there is less MITF expressed in melanoma cells than in normal melanocytes [25].”
BackgroundEmerging molecular targets in melanoma invasion and metastasis
Orgaz, J. L., & Sanz‐Moreno, V. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12041 · Cited by 127
“Other relevant downstream targets of mutant BRAF are the microphtalmia-associated transcription factor (MITF; Wellbrock and Marais, 2005), the POU-domain class 3 transcription factor BRN2 (Goodall et al., 2004) and the matrix metalloproteinase-1 (MMP-1; Huntington et al., 2004), which will be…”
BackgroundEffect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A., & Wellbrock, C. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 106
Self-citationMetabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
de la Serna, I. L., Ohkawa, Y., Higashi, C., Dutta, C., Osias, J., Kommajosyula, N., Tachibana, T., & Imbalzano, A. N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512052200 · Cited by 101
Liu, F., Fu, Y., & Meyskens, F. L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.255 · Cited by 99
“In another report, however, MiTF was downregulated in Braf-transformed murine melanocytes and BRAF-expressing human melanocytes; reexpression of MiTF in these cells inhibited cell proliferation (Wellbrock and Marais, 2005).”
BackgroundLister, J. A., Capper, A., Zeng, Z., Mathers, M. E., Richardson, J., Paranthaman, K., Jackson, I. J., & Elizabeth Patton, E. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.293 · Cited by 98
“In these contexts, exogenous expression of MITF leads to inhibition of proliferation (Selzer et al., 2002; Wellbrock and Marais, 2005).”
BackgroundRossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 99
de Keizer, P. L. J., Packer, L. M., Szypowska, A. A., Riedl-Polderman, P. E., van den Broek, N. J. F., de Bruin, A., Dansen, T. B., Marais, R., Brenkman, A. B., & Burgering, B. M. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1563 · Cited by 94
Self-citationJavelaud, D., Alexaki, V. I., Pierrat, M., Hoek, K. S., Dennler, S., van Kempen, L. C. L. T., Bertolotto, C., Ballotti, R., Saule, S., Delmas, V., et al. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00893.x · Cited by 104
“…whereby elevated expression of M-MITF may also reduce melanoma cell proliferation and invasiveness (Carreira et al., 2005, 2006; Wellbrock and Marais, 2005), while reduced M-MITF levels may provide a growth advantage to some melanoma cells, for example, through redistribution of energy and…”
BackgroundPetti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4671 · Cited by 88
Schartl, M., Wilde, B., Laisney, J. A. G. C., Taniguchi, Y., Takeda, S., & Meierjohann, S. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.213 · Cited by 94
Kunz, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1_6 · Cited by 105
POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis
Cook, A. L., & Sturm, R. A. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00510.x · Cited by 95
“…that in some human melanoma cell lines, BRN2 activates the MITF promoter as a consequence of constitutive activation of the V600EBRAF oncogene (Wellbrock et al., 2008), consistent with anti-sense RNA mediated ablation of BRN2 in a human melanoma cell line causing a loss of many melanocytic…”
BackgroundA Role for ATF2 in Regulating MITF and Melanoma Development
Shah, M., Bhoumik, A., Goel, V., Dewing, A., Breitwieser, W., Kluger, H., Krajewski, S., Krajewska, M., DeHart, J., Lau, E., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001258 · Cited by 81
“-expressing melanocytes to grow on soft agar via distinct mechanisms. Whereas specific inhibition of ATF2 causes both accumulation of cells in G2 and induction of cell death, specific alteration of MITF protein levels—particularly depletion—significantly affects cell proliferation and inhibit growth on soft agar by no…”
ResultUgurel, S., Houben, R., Schrama, D., Voigt, H., Zapatka, M., Schadendorf, D., Bröcker, E., & Becker, J. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2682 · Cited by 91
The three M’s: melanoma, microphthalmia‐associated transcription factor and microRNA
Bell, R. E., & Levy, C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00931.x · Cited by 68
“Alternatively, expression of MITF was reported to inhibit tumor growth (Selzer et al., 2002) and its downregulation was shown to facilitate proliferation of BRAF-mutated melanomas (Wellbrock and Marais, 2005; Wellbrock et al., 2008).”
BackgroundMolecular Network Associated with MITF in Skin Melanoma Development and Progression
Yajima, I., Kumasaka, M. Y., Thang, N. D., Goto, Y., Takeda, K., Iida, M., Ohgami, N., Tamura, H., Yamanoshita, O., Kawamoto, Y., et al. (2011) · Journal of Skin Cancer · doi:10.1155/2011/730170 · Cited by 82
“On the other hand, MITF directly binds to the promoter region of diaphanous homolog 1 (DIAPH1, DIA1) gene and activates its transcription, resulting in inhibiting the invasiveness of melanoma by activation of actin polymerization [95].”
BackgroundGenetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
van den Hurk, K., Niessen, H. E. C., Veeck, J., van den Oord, J. J., Steensel, M. A. M. V., Hausen, A. Z., van Engeland, M., & Winnepenninckx, V. J. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.011 · Cited by 81
The transcription factor MITF in RPE function and dysfunction
Ma, X., Li, H., Chen, Y., Yang, J., Chen, H., Arnheiter, H., & Hou, L. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.06.002 · Cited by 72
Sinnberg, T. W., Sauer, B., Holm, P. S., Spangler, B., Kuphal, S., Bosserhoff, A., & Schittek, B. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01448.x · Cited by 67
STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway
Swoboda, A., Soukup, R., Eckel, O., Kinslechner, K., Wingelhofer, B., Schörghofer, D., Sternberg, C., Pham, H. T. T., Vallianou, M., Horvath, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01584-6 · Cited by 70
Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma
Packer, L. M., East, P., Reis‐Filho, J. S., & Marais, R. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00618.x · Cited by 62
“We previously described BRN2 and MITF as targets of V600EBRAF signalling in melanoma (Goodall et al., 2004; Wellbrock and Marais, 2005), but did not find those genes in this study.”
BackgroundSelf-citationThe Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness
Cabaço, L. C., Tomás, A., Pojo, M., & Barral, D. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887366 · Cited by 62
Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”
Sharma, S. V., & Settleman, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.001 · Cited by 65
Genetics and genomics of melanoma
Ghosh, P., & Chin, L. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.2 · Cited by 74
Nakai, N., Kishida, T., Shin‐Ya, M., Imanishi, J., Ueda, Y., Kishimoto, S., & Mazda, O. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302868 · Cited by 60
Signal Transduction in Human Cutaneous Melanoma and Target Drugs
Uzdensky, A. B., Demyanenko, S. V., & Bibov, M. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313080004 · Cited by 63
“High expression of MITF suppresses proliferation of melanoma cells even in the presence of oncogenic BRAF and promotes differentiation through induction of cellular senescence and melanin production [165,177].”
BackgroundMicroRNA Cancer Regulation: Advanced Concepts, Bioinformatics and Systems Biology Tools
Schmitz, U., Wolkenhauer, O., & Vera, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1 · Cited by 58
Massi, D., Mihic‐Probst, D., Schadendorf, D., Dummer, R., & Mandalà, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102060 · Cited by 61
Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
Helgadóttir, H., Drakensjö, I. R. T., & Girnita, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00202 · Cited by 55
“MITF is regulated both through pigmentation pathways and Ras–Raf–MEK–ERK signaling (101).”
BackgroundGuo, J., Zhang, J., Wang, W.-M., Cheung, F. W. K., Lu, Y., Ng, C., Kung, H., & Liu, W.-K. (2014) · RNA Biology · doi:10.4161/rna.28865 · Cited by 53
“Forskolin, a cAMP-elevating agent, has been extensively used to enhance MITF expression.(15-17) Our results showed that the expression of MITF was significantly increased at 8 h and 12 h in melan-a cells after treatment with 20 μM of forskolin (Fig.”
MethodSmith, M. P., Rana, S., Ferguson, J., Rowling, E. J., Flaherty, K. T., Wargo, J. A., Marais, R., & Wellbrock, C. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12741 · Cited by 50
“By inducing BRN2 expression BRAF gains control over MITF, but by suppressing PAX3 it prevents high MITF expression, as this counteracts BRAF mediated proliferation (Wellbrock & Marais, 2005).”
BackgroundSelf-citationThe deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics
Giblin, W., Bringman, L. R., Guo, A. H., Kumar, S., Monovich, A. C., Mostafa, A. M., Skinner, M. E., Azar, M., Mady, A. S. A., Chung, C. H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138926 · Cited by 56
“However, this experiment is complicated by the fact that MITF overexpression itself can drive melanoma cells to leave the cell cycle and differentiate, and thus is likely selected against in shortterm culture (86).”
BackgroundCurrent Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model
Hersey, P., Zhuang, L., & Zhang, X. D. (2006) · International review of cytology · doi:10.1016/s0074-7696(06)51004-6 · Cited by 52
Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance
Popovic, A., & Tartare‐Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 50
“melanoma cells have been characterized as more aggressive, dedifferentiated and mesenchymal-like and were found to be associated with invasion and therapeutic resistance (44, 49, 51).”
BackgroundInfluentialLunasin is a novel therapeutic agent for targeting melanoma cancer stem cells
Shidal, C., Al-Rayyan, N., Yaddanapudi, K., & Davis, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11554 · Cited by 51
“The specific regulatory pathways affected by Lunasin to effect MITF and NANOG expression in melanoma ALDHhigh cells remain to be identified.”
BackgroundInfluentialMITF, the Janus Transcription Factor of Melanoma
Koludrovic, D., & Davidson, I. (2013) · Future Oncology · doi:10.2217/fon.12.177 · Cited by 42
Bianchi, A., Bagati, A., Fink, E. E., Moparthy, S., Wawrzyniak, J. A., Marvin, E. K., Battaglia, S., Jowdy, P., Kolesnikova, M., Foley, C. E., et al. (2016) · Oncogene · doi:10.1038/onc.2016.178 · Cited by 49
“These phenotypes are oppositely controlled by the master regulator of melanocyte development microphthalmia-associated transcription factor (MITF) (14, 21), which appears to play a dualistic role in melanoma progression (18, 20, 40, 41).”
BackgroundCirculating Biomarkers in Malignant Melanoma
Alegre, E., Sammamed, M., Landazuri, S. F., Zubiri, L., & González, Á. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.12.002 · Cited by 55
Gallagher, S. J., Thompson, J. F., Indsto, J. O., Scurr, L. L., Lett, M., Gao, B.-F., Dunleavey, R., Mann, G. J., Kefford, R. F., & Rizos, H. (2008) · Neoplasia · doi:10.1593/neo.08702 · Cited by 48
“MITF activity is also regulated by the MAP kinase pathway; activation of MAP kinase signaling phosphorylates MITF, which simultaneously increases its transactivation potential and targets it for degradation through the 26S proteasome [51,52].”
BackgroundMSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression
Heppt, M. V., Wang, J. X., Hristova, D. M., Wei, Z., Li, L., Evans, B., Beqiri, M., Zaman, S., Zhang, J., Irmler, M., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.038 · Cited by 48
“Hoek and Goding framed the ‘‘phenotype-switching model’’ of melanoma (Hoek and Goding, 2010) in which melanomas contain M-MITF-high ‘‘proliferative’’ and M-MITF-low ‘‘invasive, stem-like’’ subpopulations (Hoek et al., 2008, Selzer et al., 2002, Wellbrock and Marais, 2005).”
SOX10-MITF pathway activity in melanoma cells
Tudrej, K. B., Czepielewska, E., & Kozłowska−Wojciechowska, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60655 · Cited by 50
Canini (2009) · International Journal of Oncology · doi:10.3892/ijo_00000303 · Cited by 44
Lu, S., Slominski, A. T., Yang, S., Sheehan, C. E., Ross, J. S., & Carlson, J. A. (2010) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2010.01504.x · Cited by 45
Conserved Expression Signatures between Medaka and Human Pigment Cell Tumors
Schartl, M., Kneitz, S., Wilde, B., Wagner, T. U., Henkel, C. V., Spaink, H. P., & Meierjohann, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037880 · Cited by 39
Simultaneous suppression of MITF and BRAFV600E enhanced inhibition of melanoma cell proliferation
Kido, K., Sumimoto, H., Asada, S., Okada, S., Yaguchi, T., Kawamura, N., Miyagishi, M., Saida, T., & Kawakami, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01266.x · Cited by 37
Molina, D. M., Grewal, S., & Bardwell, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510590200 · Cited by 36
An adverse tumor-protective effect of IDO1 inhibition
Kenski, J. C. N., Huang, X., Vredevoogd, D. W., de Bruijn, B., Traets, J. J. H., Ibáñez‐Molero, S., Schieven, S. M., Vliet, A. V., Krijgsman, O., Kuilman, T., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100941 · Cited by 38
FOXQ1 controls the induced differentiation of melanocytic cells
Bagati, A., Bianchi, A., Moparthy, S., Kolesnikova, K., Fink, E. E., Kolesnikova, M., Roll, M. V., Jowdy, P., Wolff, D. W., Polechetti, A., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0066-y · Cited by 35
“In addition, in Melan-a cells, BRAF overexpression was reported to cause transformation [12].”
The Application of siRNA Technology to Cancer Biology Discovery
Fuchs, U., & Borkhardt, A. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)96004-7 · Cited by 40
The genetics of malignant melanoma
Lomas, J., Martín‐Duque, P., Pons, M., & Quintanilla, M. (2008) · Frontiers in bioscience · doi:10.2741/3065 · Cited by 42
“Moreover, upon transformation of murine melanocytes by oncogenic BRAF, Mitf expression is downregulated, and reexpression of Mitf inhibits proliferation of transformed melanocytes (110).”
BackgroundSOX5 is involved in balanced MITF regulation in human melanoma cells
Kordaß, T., Weber, C. E. M., Oswald, M., Ast, V., Bernhardt, M., Novak, D., Utikal, J. S., Eichmüller, S. B., & König, R. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0170-0 · Cited by 37
“The mutation results in a constantly activated kinase that permanently stimulates extracellular-signal regulated protein kinase 2 (ERK2), which in turn phosphorylates and targets MITF proteins for ubiquitin-dependent degradation via the proteasomal pathway [15] and thereby decreases the activity of MITF.”
BackgroundAdaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
Saei, A., & Eichhorn, P. J. A. (2019) · Cancers · doi:10.3390/cancers11081176 · Cited by 35
“Furthermore, it has been shown that MITF expression is lost in BRAFV600E mutated melanoma, and that a low expression of MITF leads to increased metastatic ability of melanoma cells [75].”
BackgroundLiu, F., Singh, A., Yang, Z., Garcia, A., Kong, Y., & Meyskens, F. L. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-214 · Cited by 32
“However, re-expression of MiTF in BRAF-expressing human melanocytes inhibited cell proliferation, suggesting that MiTF represses cell cycle progression [5].”
BackgroundTranscriptional Regulation in Melanoma
Mitra, D., & Fisher, D. E. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.003 · Cited by 36
Guo, X., Xu, Y., & Zhao, Z. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0328-y · Cited by 30
“naling pathway and led to MITF promotion [35-37], whereas TGFB1 was reported to be down-regulated in”
BackgroundFrom Integrated Genomics to Tumor Lineage Dependency
Garraway, L. A., & Sellers, W. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4604 · Cited by 28
“Nonetheless, the role we defined for MITF in survival of melanoma cells was unexpected because previous studies showed that its forced overexpression induces cell cycle arrest in primary melanocytes (17, 18).”
BackgroundGene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Augustine, C. K., Jung, S., Sohn, I., Yoo, J. S., Yoshimoto, Y., Olson, J. A., Friedman, H. S., Ali‐Osman, F., & Tyler, D. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0764 · Cited by 29
“Previous reports (37) have shown that oncogenic BRaf-induced increases in extracellular signal-regulated kinase activity can lead to decreased MITF expression.”
BackgroundConstitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses
Jiang, L., Campagne, C., Sundström, E., Sousa, P., Imran, S. J., Seltenhammer, M. H., Pielberg, G., Olsson, M. J., Egidy, G., Andersson, L., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-857 · Cited by 28
“The involvement of both BRAF and CRAF kinases in the ERK signaling has been previously observed in human melanocytes [30], but is rather unusual in a melanoma context.”
BackgroundLei, M.-J., Dong, Y., Sun, C., & Zhang, X. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.09.029 · Cited by 28
Cooperative behaviour and phenotype plasticity evolve during melanoma progression
Rowling, E. J., Miskolczi, Z., Nagaraju, R. T., Wilcock, D. J., Wang, P., Telfer, B. A., Li, Y., Lasheras-Otero, I., Redondo-Muñoz, M., Sharrocks, A. D., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12873 · Cited by 27
“…MITF depletion in 501mel cells result in DNA damage and induction of senescence rather than establishing a mesenchymal state (Carreira et al., 2006; Cheli, Ohanna, Ballotti, & Bertolotto, 2010; Lauss et al., 2015; Strub et al., 2011; Vachtenheim, Novotna, & Ghanem, 2001; Wellbrock & Marais, 2005).”
BackgroundSelf-citationThe AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Serini, S., Zinzi, A., Vasconcelos, R. O., Fasano, E., Riillo, M. G., Celleno, L., Trombino, S., Cassano, R., & Calviello, G. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.06.010 · Cited by 26
“In line, it was also reported that a high MITF expression inhibited melanoma cell proliferation [60].”
BackgroundGoding, C. R., & Meyskens, F. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2648 · Cited by 24
Metadata
- Authors
- Wellbrock, C., & Marais, R.
- Affiliations
- Institute of Cancer Research (GB)
- Corresponding author
- Marais, Richard
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2005-08-29
- Volume
- 170
- Issue
- 5
- Pages
- 703-708
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2171350
- OpenAlex
- W2169209908
- Cited by
- 196
- References
- 20
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 6 · 2022: 7 · 2021: 4 · 2020: 4 · 2019: 12 · 2018: 6 · 2017: 11 · 2016: 14 · 2015: 7 · 2014: 13 · 2013: 16 · 2012: 10
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- MITF, BRAF, melanoma, melanocytes, cell proliferation, transcriptional regulation, melanocyte differentiation, melanoma progression
- MeSH terms
- Cyclic AMP, Animals, Cell Line, Cell Line, Transformed, DNA-Binding Proteins, Enzyme Activation, Humans, Melanocytes, Melanoma, Transcription Factors, Signal Transduction, Down-Regulation, RNA Interference, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, Microphthalmia-Associated Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.